Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survodutide PK/Safety in Chinese Participants with Overweight or Obesity
NCT06492135Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of survodutide in obesity and Overweight (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of survodutide in plasma over the time interval from 0 to 168h, Maximum measured concentration of survodutide in plasma after the first dose up to 7 days and 1 more. Started Aug 2024; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06492135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492135.